Abstract
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).
Methods
Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.
Results
A majority of the 199 patients accrued to this study reported “quite a bit” to “very much” numbness (57%) or tingling (63%) in the hands compared to “a little” or “not at all” (numbness (43%), tingling (38%)). Fewer patients reported “quite a bit” to “very much” shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.
Conclusions
In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
Similar content being viewed by others
References
Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150
Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447
Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625
Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79
Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115
Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563
Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12(5):565–571
Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46
LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204
Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009
Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139
Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663
Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142
Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169
Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19
NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, Bethesda
Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284
Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print]
Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534
Reeves B et al (2010) Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. J Clin Oncol 28:15s (suppl; abstr 9135). doi:10.1200/JCO.2010.33.0308
Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173
Acknowledgment
This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-63848, CA-35195, CA-37417, CA-35448, CA-35267, CA-63849, CA-35113, CA-35103, CA-35415, CA-35431, CA-45377, and CA-67575. This work was also supported by the NIH Mentorship Grant CA-124477. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health.
Conflict of interest disclosure
Neil K. Aaronson, who developed the EORCT QLQ-CIPN20 instrument, works with EORTC. The other authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Additional participating institutions include: Cedar Rapids Oncology Program CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld, MD); Geisinger Clinic & Medical Center CCOP, Danville, PA 17822 (Albert M. Bernath, Jr., M.D.); Rapid City Regional Hospital, Inc, Rapid City, SD 57701 (Richard C, Tenglin, M.D.); Sioux Community Cancer Consortium, Sioux Falls, SD 57105 (Loren K. Tschetter, M.D.); Toledo Community Hospital Oncology Program (Rex Mowat, M.D.); Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN 55416 (Patrick J. Flynn, M.D.); Mayo Clinic Arizona, Scottsdale, AZ 85259-5404 (Tom R. Fitch, M.D.); Hematology/Oncology Centers of the Northern Rockies, Billings, MT 59101 (Benjamin Marchello, M.D.); Carle Cancer Center, Urbana, IL 61801 (Kendrith M. Rowland, Jr, M.D.); Spartanburg Regional Medical Center, Spartanburg, SC 29303 (James D. Bearden, III, M.D.); Columbia River Oncology Program, Portland, OR 97225 (Janet C. Ruzich, M.D.); and Illinois Oncology Research Assn. CCOP, Peoria, IL 61615–7828 (John W. Kugler, M.D.).
Rights and permissions
About this article
Cite this article
Wolf, S.L., Barton, D.L., Qin, R. et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20, 625–632 (2012). https://doi.org/10.1007/s00520-011-1141-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1141-9